6 completed, 2 terminated, 1 enrolling by invitation, 1 not yet recruiting. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Terminated 2, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Arrhythmia: new trials by email Literature Review of Arrhythmia trials Research Report on Arrhythmia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relaxin Therapy for Atrial Fibrillation Relaxin, Placebo - Atrial Fibrillation (AF), Arrhythmia | Phase 1 / Phase 2 | Not yet recruiting | Deeptankar DeMazumder | 208 | 2027-01-01 | 2026-01-22 |
| Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT) stereotactic body radiotherapy, 20 Gy in 1 fraction - Ventricular Tachycardia, Arrhythmia | Phase 2 | Enrolling by invitation | McGill University Health Centre/Research Institute of the McGill University Health Centre | 9 | 2023-07-01 | 2025-03-18 |
| A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients Control group:DH001 placebo, Trial group: DH001 low-dose group, Trial group: DH001 high-dose group - Cancer, Heart Failure | Phase 2 | Unknown | Monyan Pharmaceutical (Shanghai) Co., Ltd. | 90 | 2023-04-04 | 2023-10-23 |
| A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients AZD2927, Placebo - Arrhythmia | Phase 2 | Completed | AstraZeneca | 20 | 2011-09-01 | 2012-11-27 |
| Empiric Quinidine for Asymptomatic Brugada Syndrome quinidine, no therapy - Arrhythmia | Phase 2 / Phase 3 | Withdrawn | International Registry of Asymptomatic Brugada Syndrome | 2009-12-01 | 2020-02-13 | |
| Effects of Docosahexaenoic Acid (DHA) on Heart Rate Variability in Elderly Patients Docosahexaenoic acid (DHA), Placebo - Arrhythmia | Phase 2 / Phase 3 | Completed | Campus Bio-Medico University | 50 | 2008-06-01 | 2009-11-25 |
| Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 90 | 2005-11-01 | 2007-12-10 |
| Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis Dialysate Magnesium (Concentration) - Chronic Kidney Disease, Arrhythmia | Phase 2 | Completed | University of Michigan | 25 | 2005-11-01 | 2014-12-09 |
| Study Evaluating GAP-486 in Heart Rhythm GAP-486 (ZP-123), 0.9% Sodium Chloride, USP - Arrhythmia | Phase 2 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 30 | 2005-11-01 | 2007-12-10 |
| Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS SSR149744C - Arrhythmia, Tachycardia, Ventricular | Phase 2 | Completed | Sanofi | 153 | 2005-06-01 | 2012-05-08 |
| Antiarrhythmic Effects of N-3 Fatty Acids dietary n-3 polyunsaturated fatty acids - Arrhythmia, Heart Diseases | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1999-02-01 | 2016-02-18 | |
| Cardiac Arrhythmia Pilot Study (CAPS) encainide, moricizine, flecainide - Arrhythmia, Cardiovascular Diseases | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1982-09-01 | 2012-04-27 |
Arrhythmias, Cardiac (12) · Tachycardia, Ventricular (3) · Heart Diseases (2) · Heart Failure (2) · Ventricular Fibrillation (2) · Atrial Fibrillation (1) · Brugada Syndrome (1) · Cardiovascular Diseases (1) · Death, Sudden, Cardiac (1) · Neoplasms (1) · Radiation Injuries (1) · Renal Insufficiency, Chronic (1) · Stroke (1) · Syncope (1)
Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Cardiovascular Diseases (11) · Heart Diseases (10) · Cardiac Conduction System Disease (4) · Tachycardia (3) · Nervous System Diseases (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Consciousness Disorders (1) · Death (1) · Death, Sudden (1)
Sodium Chloride (2) · rotigaptide (2) · AZD2927 (1) · Control Groups (1) · Docosahexaenoic Acids (1) · Encainide (1) · Flecainide (1) · Imipramine (1) · Moricizine (1) · Population Groups (1) · Quinidine (1) · Radiosurgery (1) · Relaxin (1) · celivarone (1)
National Heart, Lung, and Blood Institute (NHLBI) (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · AstraZeneca (1) · Campus Bio-Medico University (1) · Deeptankar DeMazumder (1) · International Registry of Asymptomatic Brugada Syndrome (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Monyan Pharmaceutical (Shanghai) Co., Ltd. (1) · Sanofi (1) · University of Michigan (1)
United States (5) · Canada (4) · Italy (3) · Germany (2) · Netherlands (2) · Belgium (1) · China (1) · Czechia (1) · Israel (1) · Japan (1) · Norway (1) · Sweden (1) · Switzerland (1)
Allan Barker (1) · Craig Pratt (1) · David Richardson (1) · Deeptankar DeMazumder, MD, PhD (1) · Francesco M Serino, MD (1) · Giuseppe Rosano, MD (1) · Hakan Walfridsson, MD, PHD (1) · Hesheng He (1) · Hongmei Jing (1) · Hui Zhou (1) · Israel Stein (1) · J. Bigger (1) · Jiwei Liu (1)
R01HL061682 (1)